State Medicaid agencies can improve D-SNP financial transparency and reward those D-SNPs that provide the best value to ...

Special Needs Plans boosted a sluggish Medicare Advantage market during the annual enrollment period for 2025, a Modern ...

We recently published a list of 10 Tech Stocks with High Upside Potential. In this article, we are going to take a look at ...

Synopsys (NASDAQ:SNPS – Free Report) had its price target decreased by Piper Sandler from $655.00 to $653.00 in a report released on Thursday,Benzinga reports. Piper Sandler currently has an ...

(Reuters) - Synopsys is looking to sell about $10 billion of bonds as soon as next week to help finance its acquisition of ...

Synopsys Inc. is looking to sell around $10 billion of bonds as soon as next week to help finance its $34 billion acquisition ...

Synopsys SNPS shares plunged 20.8% over the past year, underperforming the Zacks Computer - Software industry, Zacks Computer ...

The polygenic risk score appears to identify patients who may benefit most from LDL-lowering therapy, say researchers.

The polygenic risk score appears to identify patients who may benefit most from LDL-lowering therapy, say researchers.

Morgan Stanley maintained its Overweight rating and the $590 price target on the shares of Synopsys — which provides ...

Stifel Nicolaus analyst Ruben Roy maintained a Buy rating on Synopsys (SNPS – Research Report) today and set a price target of $620.00. The ...

Wells Fargo analyst Joe Quatrochi lowered the firm’s price target on Synopsys (SNPS) to $520 from $540 and keeps an Equal Weight rating on the ...